Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Sparreboom

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Clinical Pharmacology and Therapeutics|December 17, 2016
Predicting transporter-mediated drug interactions: Commentary on: "Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin" and "Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A"L Zhang, A Sparreboom
Clinical Pharmacology and Therapeutics|January 20, 2009
Advances in cancer therapeuticsA Sparreboom, J Verweij
Clinical Pharmacology and Therapeutics|October 9, 2016
Drug Transporters: Advances and OpportunitiesR Govindarajan, A Sparreboom
Clinical Pharmacology and Therapeutics|December 19, 2009
Drug transporters: recent advances and therapeutic applicationsR M Franke, A Sparreboom
Clinical Pharmacology and Therapeutics|March 21, 2014
A snapshot of challenges and solutions in cancer drug development and therapyM A Phelps, A Sparreboom
Clinical Pharmacology and Therapeutics|October 23, 2012
Drug trafficking: recent advances in therapeutics and diseaseJ A Sprowl, A Sparreboom
Clinical Pharmacology and Therapeutics|March 23, 2011
Pharmaceutical relevance of drug transporter malfunctionsC S Lancaster, A Sparreboom
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Dosing strategies for anticancer drugs: the good, the bad and body-surface areaA Felici, J Verweij, A Sparreboom
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
MitomycinsJ Verweij, A Sparreboom, K Nooter
Clinical Pharmacology and Therapeutics|February 22, 2008
Influence of lean body weight on anticancer drug clearanceR H J Mathijssen, A Sparreboom
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Clinical Pharmacology and Therapeutics|December 17, 2016
Predicting transporter-mediated drug interactions: Commentary on: "Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin" and "Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A"L Zhang, A Sparreboom
Clinical Pharmacology and Therapeutics|January 20, 2009
Advances in cancer therapeuticsA Sparreboom, J Verweij
Clinical Pharmacology and Therapeutics|October 9, 2016
Drug Transporters: Advances and OpportunitiesR Govindarajan, A Sparreboom
Clinical Pharmacology and Therapeutics|December 19, 2009
Drug transporters: recent advances and therapeutic applicationsR M Franke, A Sparreboom
Clinical Pharmacology and Therapeutics|March 21, 2014
A snapshot of challenges and solutions in cancer drug development and therapyM A Phelps, A Sparreboom
Clinical Pharmacology and Therapeutics|October 23, 2012
Drug trafficking: recent advances in therapeutics and diseaseJ A Sprowl, A Sparreboom
Clinical Pharmacology and Therapeutics|March 23, 2011
Pharmaceutical relevance of drug transporter malfunctionsC S Lancaster, A Sparreboom
European Journal of Cancer (Oxford, England : 1990)|August 15, 2002
Dosing strategies for anticancer drugs: the good, the bad and body-surface areaA Felici, J Verweij, A Sparreboom
Cancer Chemotherapy and Biological Response Modifiers|May 9, 2000
MitomycinsJ Verweij, A Sparreboom, K Nooter
Clinical Pharmacology and Therapeutics|February 22, 2008
Influence of lean body weight on anticancer drug clearanceR H J Mathijssen, A Sparreboom
Pageof 13